A Novel Pre-treatment Approach to Ulcerative Colitis in a Mouse Model

Document Type : Research/Original Article


1 Department of Biochemistry, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.

2 Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Department of Pathology, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.

4 Pharmaceutical Research Center, Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.


Background: Inflammatory Bowel Disease (IBD) is a complex multifactorial disease that includes two Crohn's disease and ulcerative colitis (UC). The UC characterized by inflammation, oxidative stress, and increased intestinal epithelial cell apoptosis. The present study aiming to investigate the protective potential of a combination of five safety products: Bromelain (BR), Silibinin (SB), Alpha-lipoic acid (ALA), Inulin (IN) and Sodium butyrate (BU) against UC.
Methods: Seventy-two male Balb/c mice were divided into 9 groups, and administered for 14 days by a minimum effective dose of BR, SB, ALA, IN, BU or all together (PAC). Mesalazine (MZ) is used to compare the therapeutic effects of the compounds. Colitis was induced by rectal injection of acetic acid (4%) in 12th day. Blood and colon tissue were collected and the expression of inflammatory cytokines, and oxidative stress indices were examined using ELISA methods. The SPSS v.24 was used for data analysis.
Results: All the therapeutic groups including BR, IN, BU, ALA, SB separately, partially improved histopathological changes due to colitis, but PAC treatment prior to colitis induction significantly (p<0.001), and more effectively alleviated the extent and intensity of the histological signs of cell damage including inflammation intensity, macroscopic and microscopic colon damage, and improved colitis. A significant decrease in inflammatory cytokines and oxidative stress indices also observed in the group treated with ALA, SB and PAC.
Conclusion: This new drug combination (PAC) is more beneficial for the prevention of UC better than MZ that is a usual treatment of UC.


  1.  Feuerstein JD, Cheifetz AS, editors. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clinic Proceedings; 2014: Elsevier.
  2. Ling K-L, Ooi C-J, Luman W, Cheong W-K, Choen FS, Ng H-S. Clinical Characteristics of Ulcerative Colitis
    in Singapore, a Multiracial City–State. Journal of clinical gastroenterology. 2002;35(2):144-8.
  3. Lok KH, Hung HG, Ng CH, Kwong KC, Yip WM, Lau SF, et al. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: experience from a single center in Hong Kong. Journal of gastroenterology and hepatology. 2008;23(3):406-10.
  4. Jantchou P, Morois S, Clavel-Chapelon F, Boutron-Ruault M-C, Carbonnel F. Animal protein intake and risk
    of inflammatory bowel disease: The E3N prospective study.                                                                                      The American journal of gastroenterology. 2010;105(10):2195.
  5. Jowett S, Seal C, Pearce M, Phillips E, Gregory W, Barton J, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut. 2004;53(10):1479-84.
  6. Travis S, Stange E, Lémann M, Øresland T, Bemelman W, Chowers Y, et al. European evidence-based
    consensus on the management of ulcerative colitis: current management. Journal of Crohn’s and
    Colitis. 2008;2(1):24-62.
  7. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.
    New England Journal of Medicine. 1999;340(24):1888-99.
  8. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of
    inflammatory bowel disease in adults. Gut. 2011;60(5):571-607.
  9. Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. World journal of gastroenterology. 2016;22(3):1078.
  10. Connell W, Kamm M, Ritchie J, Lennard-Jones J. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34(8):1081-5.
  11. Hayes CE, Cerezo CS. Monoclonal Antibody Use in Inflammatory Bowel disease. Medicine and Health Rhode
    Island. 2011;94(11):337.
  12. Abdelouhab K, Rafa H, Toumi R, Bouaziz S, Medjeber O, TouilBoukoffa C. Mucosal intestinal alteration in experimental colitis correlates with nitric oxide production by peritoneal macrophages: effect
    of probiotics and prebiotics. Immunophar macology and immunotoxicology. 2012;34(4):590-7.
  13. Hale LP, Greer PK, Trinh CT, Gottfried MR. Treatment with oral bromelain decreases colonic inflammation in
    the IL-10-deficient murine model of inflammatory bowel disease. Clinical Immunology. 2005;116(2):135-42.
  14. Kane S, Goldberg MJ. Use of bromelain for mild ulcerative colitis. Annals of internal medicine. 2000;132(8):680.
  15. Chobotova K, Vernallis AB, Majid FAA. Bromelain’s activity and potential as an anti-cancer agent:
    current evidence and perspectives. Cancer letters. 2010;290(2):148-56.
  16. Leenen CH, Dieleman LA. Inulin and oligofructose in chronic inflammatory bowel disease. The Journal of
    Nutrition. 2007;137(11):2572S-5S.
  17. Guarner F. Inulin and oligofructose: impact on intestinal diseases and disorders.                                                          British Journal of Nutrition. 2005;93(S1):S61-S5.
  18. Vernia P. Butyrate in the treatment of ulcerative colitis. Digestive and Liver Disease Supplements. 2007;1(1):27-30.
  19. Schnekenburger M, Diederich M. Nutritional epigenetic regulators in the field of cancer: new avenues for chemopreventive approaches. Epigenetic cancer therapy: Elsevier; 2015. p. 393-425.
  20. Kolgazi M, Jahovic N, Yüksel M, Ercan F, Alican I. α‐Lipoic acid modulates gut inflammation induced by trinitrobenzene sulfonic acid in rats. Journal of gastroenterology and hepatology. 2007;22(11):1859-65.
  21. Zheng R, Ma J, Wang D, Dong W, Wang S, Liu T, et al. Chemopreventive Effects of Silibinin on ColitisAssociated Tumorigenesis by Inhibiting IL-6/STAT3 Signaling Pathway. Mediators of inflammation 2018;2018.
  22. Wan P, Chen H, Guo Y, Bai A-P. Advances in treatment of ulcerative colitis with herbs: from bench to bedside. World
    Journal of Gastroenterology: WJG. 2014;20(39):14099.
  23. Vieira EL, Leonel AJ, Sad AP, Beltrão NR, Costa TF, Ferreira TM, et al. Oral administration of sodium butyrate
    attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. The Journal of nutritional
    biochemistry. 2012;23(5):430-6.
  24. Trivedi P, Jena G. Role of α-lipoic acid in dextran sulfate sodium-induced ulcerative colitis in mice: studies on inflammation, oxidative stress, DNA damage and fibrosis. Food and chemical toxicology. 2013;59:339-55.
  25. Kauntz H, Bousserouel S, Gosse F, Marescaux J, Raul F. Silibinin, a natural flavonoid, modulates the
    early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis.
    International journal of oncology. 2012;41(3):849-54.
  26. Atarbashe RK, Abu-Raghif A. Comparative treatment of induced ulcerative colitis in male rat model by
    using cinnarizine and sulfasalazine. Iraqi Journal of Veterinary Sciences. 2020;34(2):465-72.
  27. Mousavizadeh K, Rahimian R, Fakhfouri G, Aslani F, Ghafourifar P. Anti‐inflammatory effects of 5‐HT3 receptor antagonist, tropisetron on experimental colitis in rats. European journal of                                                            clinical investigation. 2009;39(5):375-83.
  28. Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider-Trejo L, Lee J, et al. Immunostimulatory DNA ameliorates
    experimental and spontaneous murine colitis. Gastroenterology. 2002;122(5):1428-41.
  29. Pavan R, Jain S, Kumar A. Properties and therapeutic application of bromelain: a review. Biotechnology research international. 2012;2012.
  30. Johannsen F. Toxicological profile of carboxymethyl inulin. Food and chemical toxicology. 2003;41(1):49-59.
  31. Egorin MJ, Yuan Z-M, Sentz DL, Plaisance K, Eiseman JL. Plasma pharmacokinetics of butyrate after
    intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice
    and rats. Cancer chemotherapy and pharmacology. 1999;43(6):445-53.
  32. Cremer D, Rabeler R, Roberts A, Lynch B. Safety evaluation of α-lipoic acid (ALA). Regulatory Toxicology
    and Pharmacology. 2006;46(1):29-41
  33. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytotherapy Research. 2010;24(10):1423-32.
  34. K hoshak hlagh P B-SM, Mohammadirad A, Ashtaral-Nakhai L, Minaie B, Abdollahi M. . Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for
    involvement of oxidative stress. Toxicology mechanisms and methods. 2007;17(5):281-8.
  35. Araki Y, Sugihara H, Hattori T. The free radical scavengers edaravone and tempol suppress experimental
    dextran sulfate sodium-induced colitis in mice. International journal of molecular medicine. 2006;17(2):331-4.
  36. Rees V. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2
    cytokines. Clinical & Experimental Immunology. 1998;114(3):385-91.
  37. Nishiyama Y, Kataoka T, Yamato K, Taguchi T, Yamaoka K. Suppression of dextran sulfate sodium-induced colitis in mice by radon inhalation. Mediators of inf lammation. 2012;2012.
  38. Rathnavelu V, Alitheen NB, Sohila S, Kanagesan S, Ramesh R. Potential role of bromelain in clinical and
    therapeutic applications. Biomedical reports. 2016;5(3):283-8.
  39. Nicola WG, Girgiss MW, El-Arab AME, Habib DF, Elnemr ME, Ahmed NM. Role of Inulin in the Protection and Management of Metabolic Inflammation in Humans by. Biomedical and Pharmacology Journal. 2018;11(2):1083-90.
  40. Bach Knudsen K, Lærke H, Hedemann M, Nielsen T, Ingerslev A, Gundelund Nielsen D, et al. Impact of diet-modulated butyrate production on intestinal barrier function and inflammation. Nutrients. 2018;10(10):1499.
  41. Kiemer AK, Müller C, Vollmar AM. Inhibition of LPS‐induced nitric oxide and TNF‐α production by α‐lipoic acid
    in rat Kupffer cells and in RAW 264.7 murine macrophages. Immunology and cell biology. 2002;80(6):550-7.
  42. Tong W, Zhang C, Hong T, Liu D, Wang C, Li J, et al. Silibinin alleviates inflammation and induces apoptosis
    in human rheumatoid arthritis fibroblast-like synoviocytes and has a therapeutic effect on arthritis in rats.
    Scientific reports. 2018;8(1):3241.
  43. Elsherif Y, Alexakis C, Mendall M. Determinants of weight loss prior to diagnosis in inflammatory bowel
    disease: a retrospective observational
      study. Gastroenterology research and practice. 2014;2014.
  44. Videla S, Vilaseca J, Antolín M, García-Lafuente A, Guarner F, Crespo E, et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. The American journal of gastroenterology. 2001;96(5):1486.
  45. Malago JJ, Sangu CL. Intraperitoneal administration of butyrate prevents the severity of acetic acid colitis in
    rats. Journal of Zhejiang UniversitySCIENCE B. 2015;16(3):224-34.
  46. Sun J, Zhang H, Guan L, Zhou H, Sun M. Alpha-lipoic acid attenuates trinitrobenzene sulfonic acid-induced
    ulcerative colitis in mice. International journal of clinical and experimental medicine. 2015;8(1):358.
  47. Kuethe F, Figulla HR, Herzau M, Voth M, Fritzenwanger M, Opfermann T, et al. Treatment with granulocyte
    colony–stimulating factor for mobilization of bone marrow cells in patients with acute myocardial
    infarction. American heart journal. 2005;150(1):115.
  48. Takač B, Mihaljević S, Štefanić M, Glavaš-Obrovac L, Kibel A, Samardžija M. Importance of interleukin 6 in pathogenesis of inflammatory bowel disease. Collegium antropologicum. 2014;38(2):659-64.
  49. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation
    of NF-κB, c-Jun N-terminal kinase, and apoptosis. The Journal of Immunology. 1999;163(12):6800-9.
  50. Zhao J, Sharma Y, Agarwal R. Significant inhibition by the flavonoid antioxidant silymarin against 12‐O‐tetradecanoylphorbol 13‐acetate–caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin‐1α expression in SENCAR mouse epidermis: Implications in the prevention of stage I tumor promotion. Molecular carcinogenesis. 1999;26(4):321-33.
  51. Osuchowski M, Johnson V, He Q, Sharma R. Alterations in regional brain neurotransmitters by silymarin, a
    natural antioxidant flavonoid mixture, in BALB/c mice. Pharmaceutical biology. 2004;42(4-5):384-9.
  52. Esmaily H, Hosseini-Tabatabaei A, Rahimian R, Khorasani R, Baeeri M, Barazesh-Morgani A, et al. On the
    benefits of silymarin in murine colitis by improving balance of destructive cytokines and reduction of toxic stress
    in the bowel cells. Central European Journal of Biology. 2009;4(2):204.
  53. Onken JE, Greer PK, Calingaert B, Hale LP. Bromelain treatment decreases secretion of proinf lammatory cytokines and chemokines by colon biopsies in vitro. Clinical Immunology. 2008;126(3):345-52.
  54. Zhou Z, Wang L, Feng P, Yin L, Wang C, Zhi S, et al. Inhibition of epithelial TNF-α receptors by purified
    fruit bromelain ameliorates intestinal inflammation and barrier dysfunction in colitis.                                          Frontiers in immunology. 2017;8:1468.
  55. Pool-Zobel BL. Inulin-type fructans and reduction in colon cancer risk: review of experimental and human
    data. British Journal of Nutrition. 2005;93(S1):S73-S90.
  56. Shahzad Z, Rouached H, Rakha A. Combating mineral malnutrition through iron and zinc biofortification
    of cereals. Comprehensive Reviews in Food Science and Food Safety. 2014;13(3):329-46.
  57. Plöger S, Stumpff F, Penner GB, Schulzke JD, Gäbel G, Martens H, et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract. Annals of the New York Academy of Sciences. 2012;1258(1):52-9.
  58. Kovarik JJ, Tillinger W, Hofer J, Hölzl MA, Heinzl H, Saemann MD, et al. Impaired anti‐inflammatory
    efficacy of n‐butyrate in patients with IBD. European journal of clinical investigation. 2011;41(3):291-8.
  59. Diakos C, Prieschl EE, Säemann MD, Böhmig GA, Csonga R, Sobanov Y, et al. n-Butyrate inhibits Jun NH
    (2)-terminal kinase activation and cytokine transcription in mast cells. Biochemical and biophysical research
    communications. 2006;349(2):863-8.
  60. Assisi R. Combined butyric acid/ mesalazine treatment in ulcerative colitis with mild-moderate activity.
    Results of a multicentre pilot study. Minerva gastroenterologica e dietologica. 2008;54(3):231-8.
  61. Chen G, Ran X, Li B, Li Y, He D, Huang B, et al. Sodium Butyrate Inhibits Inflammation and Maintains
    Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model.                                EBioMedicine. 2018;30:317-25.
  62. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost F, Brummer RJ. The role of butyrate on colonic
    function. Alimentary pharmacology & therapeutics. 2008;27(2):104-19.
  63. Pravda J. Radical induction theory of ulcerative colitis. World journal of gastroenterology: WJG. 2005;11(16):2371.
  64. Karp SM, Koch TR. Oxidative stress and antioxidants in inflammatory bowel disease.                                           Disease-a-Month. 2006;5(52):199-207.
  65. McLennan SV, Heffernan S, Wright L, Rae C, Fisher E, Yue DK, et al. Changes in hepatic glutathione metabolism in diabetes. Diabetes. 1991;40(3):344-8.
  66. Rezaei N, Eftekhari MH, Tanideh N, Mokhtari M, Bagheri Z. Protective Effects of Honey and Spirulina
    Platensis on Acetic Acid-Induced Ulcerative Colitis in Rats. Iranian Red Crescent Medical Journal. 2018(In Press).
  67. Nieto N, Torres M, Fernandez M, Giron M, Rios A, Suarez M, et al. Experimental ulcerative colitis impairs antioxidant defense system in rat intestine. Digestive diseases and sciences. 2000;45(9):1820-7.